Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Pharma/Biotech Companies - In the News
>
Aducanumab’s day of reckoning approaches
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="cafead, post: 6469132, member: 1"]via Biogen’s fortunes depend on it getting approval for its Alzheimer’s candidate aducanumab. The company's lacklustre third-quarter results, announced Wednesday, emphasised this fact.</p><p><br /></p><p>The project faces an US FDA advisory committee on November 6, and the agency usually – but not always – follows the advice of its panels, so the outcome will be a big indicator of whether aducanumab will get the nod. But predicting which way the panel will swing is tough: on the one hand is aducanumab's unconvincing efficacy and safety, and on the other a dire lack of options for Alzheimer’s patients.</p><p><br /></p><p><a href="https://bit.ly/3joMu5F" target="_blank" class="externalLink ProxyLink" data-proxy-href="https://bit.ly/3joMu5F" rel="nofollow">article source</a>[/QUOTE]</p><p><br /></p>
[QUOTE="cafead, post: 6469132, member: 1"]via Biogen’s fortunes depend on it getting approval for its Alzheimer’s candidate aducanumab. The company's lacklustre third-quarter results, announced Wednesday, emphasised this fact. The project faces an US FDA advisory committee on November 6, and the agency usually – but not always – follows the advice of its panels, so the outcome will be a big indicator of whether aducanumab will get the nod. But predicting which way the panel will swing is tough: on the one hand is aducanumab's unconvincing efficacy and safety, and on the other a dire lack of options for Alzheimer’s patients. [url="https://bit.ly/3joMu5F"]article source[/url][/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Pharma/Biotech Companies - In the News
>
Aducanumab’s day of reckoning approaches
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Pharma/Biotech Companies - In the News
>
Aducanumab’s day of reckoning approaches
>